Papillary Adenoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Papillary Adenoma

MalaCards integrated aliases for Papillary Adenoma:

Name: Papillary Adenoma 12 15 70
Glandular Papilloma 12 70
Adenoma 44 70


External Ids:

Disease Ontology 12 DOID:3172
MeSH 44 D000236
NCIt 50 C79951
SNOMED-CT 67 86143001
UMLS 70 C0001430 C0205650 C3282896

Summaries for Papillary Adenoma

MalaCards based summary : Papillary Adenoma, also known as glandular papilloma, is related to ceruminoma and wolffian duct adenoma. An important gene associated with Papillary Adenoma is KRT7 (Keratin 7), and among its related pathways/superpathways are ErbB signaling pathway and MicroRNAs in cancer. The drugs Clopidogrel and Scopolamine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, colon and prostate, and related phenotypes are mortality/aging and neoplasm

Related Diseases for Papillary Adenoma

Diseases related to Papillary Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1906)
# Related Disease Score Top Affiliating Genes
1 ceruminoma 32.4 KRT7 KRT5
2 wolffian duct adenoma 32.3 KRT7 AMACR
3 intracystic papillary adenoma 32.2 KRT5 CEACAM5
4 nephrogenic adenoma of urinary bladder 32.2 KRT7 AMACR
5 middle ear adenoma 32.1 SYP KRT7
6 urinary bladder villous adenoma 32.0 KRT7 CEACAM5
7 renal adenoma 31.9 TFE3 KRT7 AMACR
8 periampullary adenoma 31.9 KRAS HRAS
9 colorectal adenoma 31.9 TP53 KRAS HRAS
10 urethral villous adenoma 31.9 KRT7 CEACAM5
11 pleomorphic adenoma 31.9 VIM TP53 KRT7 HRAS
12 nephrogenic adenoma of the urethra 31.9 KRT7 KRT5 AMACR
13 chromophil adenoma of the kidney 31.9 TFE3 KRT7 AMACR
14 vaginal tubulovillous adenoma 31.8 SYP KRT7 CEACAM5
15 vaginal adenoma 31.7 SYP KRT7
16 eccrine papillary adenoma 31.7 KRT7 KRT5 KRAS HRAS CEACAM5
17 intrahepatic bile duct adenoma 31.5 TP53 KRT7 CEACAM5
18 cervical adenoma malignum 31.4 TP53 KRT7
19 epithelial-myoepithelial carcinoma 31.4 VIM TP53 KRT7 HRAS
20 eccrine acrospiroma 31.4 KRT7 KRT5 CEACAM5
21 endometrial adenocarcinoma 31.1 TP53 KRT7 KRAS
22 lung adenoma 31.0 TP53 SFTPC SCGB1A1 KRAS HRAS
23 secretory meningioma 30.9 VIM KRT7 CEACAM5
24 subareolar duct papillomatosis 30.8 KRT7 KRT5
25 adenoma 30.7 TP53 SYP KRT7 KRAS
26 urethral diverticulum 30.7 KRT7 AMACR
27 apocrine adenocarcinoma 30.6 KRT7 KRT5
28 syringoma 30.5 VIM KRT7 CEACAM5
29 syringocystadenoma papilliferum 30.4 VIM KRAS
30 thyroid carcinoma, familial medullary 30.3 NKX2-1 KRAS CEACAM5
31 metanephric adenoma 30.3 VIM KRT7 AMACR
32 neuroendocrine tumor 30.3 SYP NKX2-1 HRAS
33 cystitis 30.3 VIM TP53 KRT7
34 myoepithelial carcinoma 30.3 VIM TP53 KRT7 HRAS
35 adenocarcinoma in situ 30.2 KRT7 KRAS CEACAM5
36 rectum cancer 30.2 KRAS HRAS CEACAM5
37 thyroid gland medullary carcinoma 30.1 SYP NKX2-1 CEACAM5
38 myh-associated polyposis 30.1 KRAS HRAS
39 appendix adenocarcinoma 30.1 SYP KRT7 KRAS HRAS
40 tubular adenocarcinoma 30.1 SYP KRT7 CEACAM5
41 anal paget's disease 30.1 KRT7 CEACAM5
42 epithelial predominant wilms' tumor 30.1 KRT7 AMACR
43 alveoli adenoma 30.1 SFTPC SCGB1A1 NKX2-1
44 chordoma 30.1 VIM TP53 KRT7
45 squamous cell papilloma 30.0 TP53 HRAS
46 hidrocystoma 30.0 KRT7 CEACAM5
47 ceruminous adenocarcinoma 30.0 KRT7 KRT5
48 urachal adenocarcinoma 30.0 KRAS CEACAM5
49 papillary carcinoma 30.0 SYP NKX2-1 KRT7
50 adenoid cystic carcinoma 30.0 VIM TP53 KRT7 KRT5 KRAS HRAS

Graphical network of the top 20 diseases related to Papillary Adenoma:

Diseases related to Papillary Adenoma

Symptoms & Phenotypes for Papillary Adenoma

MGI Mouse Phenotypes related to Papillary Adenoma:

# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 10 AMACR HRAS KRAS KRT5 NKX2-1 OGG1
2 neoplasm MP:0002006 9.7 HRAS KRAS NKX2-1 OGG1 SCGB1A1 SFTPC
3 normal MP:0002873 9.61 HRAS KRAS NKX2-1 OGG1 SCGB1A1 SYP
4 respiratory system MP:0005388 9.17 HRAS KRAS NKX2-1 SCGB1A1 SFTPC TP53

Drugs & Therapeutics for Papillary Adenoma

Drugs for Papillary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 386)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
Scopolamine Approved, Investigational Phase 4 51-34-3, 6533-68-2 5184
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
Cefazolin Approved Phase 4 25953-19-9 33255 656510
Cefdinir Approved Phase 4 91832-40-5 6915944
Sulfamethoxazole Approved Phase 4 723-46-6 5329
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
Dyclonine Approved Phase 4 586-60-7 3180
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
Simethicone Approved Phase 4 8050-81-5
Pasireotide Approved Phase 4 396091-73-9 9941444
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
Metformin Approved Phase 4 657-24-9 4091 14219
Sodium sulfate Approved, Vet_approved Phase 4 7757-82-6
Liraglutide Approved Phase 4 204656-20-2 44147092
Quinagolide Approved, Investigational Phase 4 87056-78-8, 97805-50-0 105105
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
Lactitol Approved, Investigational Phase 4 585-86-4 157355
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
Acetaminophen Approved Phase 4 103-90-2 1983
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
Codeine Approved, Illicit Phase 4 76-57-3 5284371
Octreotide Approved, Investigational Phase 4 83150-76-9 6400441 383414
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
27 Purinergic P2Y Receptor Antagonists Phase 4
28 Antiparasitic Agents Phase 4
29 Antiprotozoal Agents Phase 4
30 Cytochrome P-450 Enzyme Inhibitors Phase 4
31 Parasympatholytics Phase 4
32 Anticonvulsants Phase 4
33 Cholinergic Agents Phase 4
34 Muscarinic Antagonists Phase 4
35 Bromides Phase 4
36 Butylscopolammonium Bromide Phase 4
37 Cholinergic Antagonists Phase 4
38 cefuroxime axetil Phase 4
39 Cephalosporins Phase 4
40 Folic Acid Antagonists Phase 4
41 Clindamycin phosphate Phase 4
42 Clindamycin palmitate Phase 4
43 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
44 Antimalarials Phase 4
45 Pharmaceutical Solutions Phase 4
46 Hormones Phase 4
47 Hormone Antagonists Phase 4
48 Proton Pump Inhibitors Phase 4
49 Cathartics Phase 4
50 Laxatives Phase 4

Interventional clinical trials:

(show top 50) (show all 695)
# Name Status NCT ID Phase Drugs
1 Efficacy and Cost-effectiveness of Colonoscopy vs. Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia (eCOLO-FITS): A Randomized Multicenter Trial Unknown status NCT01767870 Phase 4
2 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
3 Prophylactic Pancreatic Duct Stent Placement After Endoscopic Snare Papillectomy of Duodenal Major Papillary Tumors; Prospective, Randomized, Controlled Study Unknown status NCT01737463 Phase 4
4 Does Hyoscine N-butylbromide Administered During Colonoscopy Increase the Polyp Detection Rate? a Randomized, Single Center, Double Blind, Placebo-controlled Study Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
5 A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Impact of Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Unknown status NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
6 Comparison of the Efficacy and Tolerability Between 3-L and 4-L Polyethylene Glycol in Bowel Preparation Unknown status NCT03356015 Phase 4 4L Polyethylene Glycol;3L Polyethylene Glycol
7 Premedication Dyclonine Improves Visibility During Bowel Cleansing for Colonoscopy Unknown status NCT03352700 Phase 4 3L PEG;3L PEG+Dyclonine Hydrochloride Mucilage
8 Impact of Reinforced Education by Wechat and Short Message Service on the Quality of Bowel Preparation Unknown status NCT02832869 Phase 4
9 Clinical Effectiveness of Serum Chromogranin A (CgA) Levels on Diagnostic Relevance, Response After Surgical Resection and Recurrence of Pancreatic Endocrine Tumors (PET) Unknown status NCT02759718 Phase 4
10 Can Involvement of Endoscopy Nurse Participation Increase Adenoma Detection Rate During Screening Colonoscopy?:A Prospective Multicenter Randomized Trial Completed NCT01124266 Phase 4
12 Evaluation of the Effects of Monopolar Transurethral Resection Versus Bipolar Transurethral Resection and Holmium Laser Enucleation of the Prostate on Urinary and Sexual Function; a Prospective Comparative Study. Completed NCT01810068 Phase 4
13 Green Light Laser (XPS) Photoselective Vaporization of the Prostate (PVP) Versus Bipolar Transurethral Vaporization (B.TUVP) of the Prostate for Treatment of Small to Moderate Sized Benign Prostate Hyperplasia: A Randomized Study Completed NCT02283684 Phase 4
14 Randomized Study Comparing Holmium Laser Enucleation of the Prostate (HOLEP) Versus Greenlight (XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) in the Management of Infravesical Obstruction Secondary to BPH Completed NCT01494337 Phase 4
15 Comparative Efficacy of Water & Indigo Carmine vs Water or Air Method Completed NCT01607255 Phase 4 Indigo carmine
16 The Effect Of Adding High Dose Simethicone To A Standard Polyethylene Glycol Preparation On Adenoma Detection Rate During Screening Colonoscopy: A Randomized Controlled Pilot Trial Completed NCT03119168 Phase 4 Simethicone Solution
17 Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection(ESD) for Gastric Adenoma or Early Gastric Cancer. Completed NCT02638584 Phase 4 Ilaprazole;Rabeprazole
18 Does Surgical Debulking Of Pituitary Adenomas Improve Responsiveness To Octreotide LAR In The Treatment Of Acromegaly: An Investigator-Initiated Study Completed NCT01371643 Phase 4 Octreotide LAR
19 Preoperative Octreotide Treatment of Patients With Growth Hormone Producing Pituitary Adenomas Completed NCT00521300 Phase 4 Octreotide
20 A Multicentre Randomized Parallel Group Phase IV Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen. Completed NCT03742232 Phase 4 PEG3350;Macrogol 4000
21 Effect of Gum Chewing on Bowel Cleansing Before Colonoscopy: A Prospective Randomized Study Completed NCT02507037 Phase 4 polyethylene glycol
22 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment: Correlation With Disease Activity, Insulin Sensitivity and Secretion Parameters Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
23 A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
24 PRolaCT - Three Multicenter Prolactinoma Randomized Clinical Trials Recruiting NCT04107480 Phase 4 Dopamine Agonists
25 Comparison Between a 1L of Polyethylene Glycol+Ascorbic Acid as a Split Dose Bowel Preparation for Colonoscopy: Prospective, Randomized, Parallel, Multi-center Trial Recruiting NCT04758156 Phase 4 CleanViewAL;SUPREP
26 Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery Active, not recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
27 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline;Pasireotide
28 Phase IV, Open-label, Multi-center, Single-arm Study of the Safety and Efficacy of Everolimus (Afinitor) in Adult Patients With Local Advanced or Metastatic, Well Differentiated Progressive Pancreatic Neuroendocrine Tumors (pNET) in China. Active, not recruiting NCT02842749 Phase 4 everolimus
29 Transanal Endoscopic Microsurgery Versus Endoscopic Submucosal Dissection For Large Rectal Adenomas Suspended NCT01023984 Phase 4
30 Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding Terminated NCT02032784 Phase 4 octreotide
31 GRAND BLEU Study: Does the Colonoscopy With Instillation of Blue Water (Indigo Carmin® Dilute) Enable an Improved Rate of Adenoma Detection for Colonoscopy With Insufflation of Air? Unknown status NCT01937429 Phase 3
32 Efficacy of Bispectral Index Monitoring for Midazolam and Meperidine Induced Sedation During Endoscopic Submucosal Dissection Unknown status NCT01157598 Phase 3
33 Calcium Plus Vitamin D Supplementation in Prevention of Colorectal Adenomas Recurrence:a Prospective, Randomized, Placebo-controlled, Multicenter Clinical Trial Unknown status NCT02143505 Phase 2, Phase 3 Ca plus vit D
34 A Randomized Trial of Berberine Hydrochloride to Prevent Colorectal Adenomas in Patients With Previous Colorectal Cancer Unknown status NCT03281096 Phase 2, Phase 3 Berberine hydrochloride;Placebo
35 Efficiency of Ursodesoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis Patients. URSOPAF Unknown status NCT00134758 Phase 2, Phase 3 Ursodeoxycholic acid;Placebo
36 A Prospective Comparative Study of Papillectomy Completed NCT02165852 Phase 3
37 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
38 Towards Cost-effective Management of Patients With Hypertension Due to Primary Aldosteronism: Adrenal Vein Sampling or Ct-scan? Completed NCT01096654 Phase 3
39 Colorectal Adenoma Chemoprevention Trial Using Aspirin: A Phase III Study Completed NCT00002527 Phase 3 aspirin
40 Dopamine Agonist Cabergoline in Residual Clinically Nonfunctioning Pituitary Adenoma After Transphenoidal Surgery: A Single Center, Open Label and Randomized Clinical Trial Completed NCT03271918 Phase 3 Cabergoline
41 Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP) Completed NCT00141193 Phase 3 Celecoxib
42 A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of Colorectal Adenomas Completed NCT00282386 Phase 3 MK0966; Rofecoxib / Duration of Treatment: 156 weeks;Placebo/ Duration of Treatment: 156 weeks
43 A Randomized, Placebo-controlled, Multicenter, Prospective Clinical Study of Berberine Hydrochloride in Preventing Recurrence and Carcinogenesis After Endoscopic Removal of Colorectal Adenomas Completed NCT02226185 Phase 2, Phase 3 Berberine hydrochloride;placebo
44 Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
45 CSP #380 - Prospective Evaluation of Risk Factors for Large (> 1 CM) Colonic Adenomas in Asymptomatic Subjects Completed NCT00032344 Phase 3
46 Prevention of Sporadic Colorectal Adenomas With Celecoxib Completed NCT00005094 Phase 3 celecoxib
47 Prevention of Progression of Duodenal Adenomas to Cancer in Patients With Familial Adenomatous Polyposis (FAP) Completed NCT00808743 Phase 2, Phase 3 Celecoxib;Ursodeoxycholic acid;Placebo
48 Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet. Completed NCT03027557 Phase 3 Cinacalcet 30 mg Tablet;Denosumab Inj 60 mg/ml
49 Polyp Prevention Trial Completed NCT00339625 Phase 3
50 Vitamin D/Calcium Polyp Prevention Study Completed NCT00153816 Phase 2, Phase 3 Calcium Carbonate;Vitamin D3;placebo

Search NIH Clinical Center for Papillary Adenoma

Inferred drug relations via UMLS 70 / NDF-RT 51 :

Octreotide Acetate

Cochrane evidence based reviews: adenoma

Genetic Tests for Papillary Adenoma

Anatomical Context for Papillary Adenoma

MalaCards organs/tissues related to Papillary Adenoma:

Pituitary, Colon, Prostate, Thyroid, Eye, Pancreas, Liver

Publications for Papillary Adenoma

Articles related to Papillary Adenoma:

(show top 50) (show all 319)
# Title Authors PMID Year
Distal Tubular Hyperplasia: A Proposal for a Unique Form of Renal Tubular Proliferation Distinct From Papillary Adenoma. 61
33560656 2021
Papillary Neoplasms of the Salivary Duct System: A Review. 61
33526223 2021
Characteristics of contrast-enhanced ultrasound in carcinogenesis of gallbladder papillary adenoma: A case report. 61
33579828 2021
AKT1 Mutations in Peripheral Bronchiolar Papilloma: Glandular Papilloma and Mixed Squamous Cell and Glandular Papilloma Is Distinct From Bronchiolar Adenoma. 61
32868527 2021
Sialadenoma Papilliferum of the Bronchus: An Unrecognized Bronchial Counterpart of the Salivary Gland Tumor With Frequent BRAF V600E Mutations. 61
33443864 2021
Benign Endobronchial Tumors: A Clinicopathologic Review. 61
33748183 2021
Clinicopathological and Molecular Characterization of Papillary Renal Neoplasm with Reverse Polarity and Its Renal Papillary Adenoma Analogue. 61
33351968 2020
Pathological features and outcomes of incidental renal cell carcinoma in candidate solid organ donors. 61
32855366 2020
[Pulmonary papillary adenoma: report of a case]. 61
33287525 2020
Massive Relief: Papillary Adenoma of the Lung in Asymptomatic Former Smoker Patient. 61
33171926 2020
Risk factors for delayed hemorrhage after endoscopic sphincterotomy. 61
31983673 2020
Novel endoscopic papillectomy for reducing postoperative adverse events (with videos). 61
33177797 2020
Retrospective study of clinical and pathologic features of pulmonary papillary adenoma: A rare tumor and 15 cases report. 61
33126399 2020
Endoscopic papillectomy for ampullary adenoma and early adenocarcinoma: analysis of factors related to treatment outcome and long-term prognosis. 61
33107134 2020
Adenocarcinoma-Papillary Cystic Pattern Arising in a Mixed Squamous and Glandular Papilloma of the Lung. 61
32098550 2020
Solitary glandular papilloma of the lung with molecular analysis: A case report and literature review. 61
32139260 2020
Thyroid-related hormones as potential markers of hypoxia/ischemia. 61
32146707 2020
Pulmonary peripheral glandular papilloma and mixed squamous cell and glandular papilloma frequently harbour the BRAF V600E mutation. 61
32096885 2020
Alterations of the bile microbiome in primary sclerosing cholangitis. 61
31243055 2020
Renal cell tumors with an entrapped papillary component: a collision with predilection for oncocytic tumors. 61
31444626 2020
Diagnosis and management of glandular papilloma of lung: A case report. 61
32258080 2020
[Successful intraductal radiofrequency ablation of residual adenoma tissue following endoscopic papillectomy]. 61
32198738 2020
Pulmonary papillary adenoma with malignant transformation: report of one case and review of the literature. 61
32355529 2020
Cytological Features of Pulmonary Papillary Adenoma with Malignant Transformation and Literature Review. 61
33282636 2020
Mixed squamous cell and glandular papilloma of the lung-A case report and literature review in Japan. 61
32114350 2020
Validation of Region of Interest Measurements for the Objective Assessment of Post-Contrast Enhancement of Renal Lesions on MRI. 61
31365281 2019
Integrated Molecular Analysis of Papillary Renal Cell Carcinoma and Precursor Lesions Unfolds Evolutionary Process from Kidney Progenitor-Like Cells. 61
31381885 2019
[Surgery of Papillary Adenoma;Report of a Case]. 61
31506417 2019
[Anatomoclinical and immunohistochemical study of hidradenoma papilliferum, a tumor deriving from anogenital mammary-like glands]. 61
31285043 2019
Rare Huge Tubular Papillary Adenoma on the Buttock Demonstrated by Magnetic Resonance Imaging (MRI). 61
31406100 2019
Allosteric and ATP-Competitive Inhibitors of mTOR Effectively Suppress Tumor Progression-Associated Epithelial-Mesenchymal Transition in the Kidneys of Tsc2+/- Mice. 61
31207499 2019
Malignant rhabdoid tumor of the musk gland and systemic T-cell lymphoma in a masked palm civet (Paguma larvata). 61
31092741 2019
A case of intraductal papillary neoplasm of the bile duct that developed 38 years after choledochoduodenostomy with invasive adenocarcinoma and lymph node metastasis. 61
31175474 2019
Surgical Resection of Endobronchial Glandular Papilloma. 61
30309633 2019
[Clinicopathological analysis of pulmonary mixed squamous cell and glandular papilloma]. 61
30955271 2019
Endoscopic Papillectomy for Major and Minor Papillary Adenoma in Familial Adenomatous Polyposis. 61
31620503 2019
Papillary Adenomas and Other Small Epithelial Tumors in the Kidney: An Autopsy Study. 61
30418186 2019
A 17-year-old woman with a solitary, mixed squamous cell and glandular papilloma of the bronchus. 61
30519472 2019
Mixed squamous cell and glandular papilloma of the lung: A case report of a novel mutation in the BRAF gene and coexistent HPV infection, possible relationship to ciliated muconodular papillary tumor. 61
30664316 2019
Histologic characteristics and prognosis of lung mixed squamous cell and glandular papilloma: six case reports. 61
31934202 2019
Coexistence of glandular papilloma and sclerosing pneumocytoma in the bronchiole. 61
29696743 2018
AMACR Positive Papillary Renal Adenomatosis and Multifocal Papillary Carcinoma in End Stage Renal Disease. 61
29887709 2018
MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma. 61
29549624 2018
A unique case of a huge mixed squamous cell and glandular papilloma of non-endobronchial origin with a peripheral growth. 61
29977775 2018
Tubulopapillary Cystic Adenoma With Apocrine Differentiation: A Unifying Concept for Syringocystadenoma Papilliferum, Apocrine Gland Cyst, and Tubular Papillary Adenoma. 61
28033156 2017
Genitourinary Malignancies in Transplant or Dialysis Patients: The Frequency of Two Newly Described 2016 World Health Organization Histopathologic Types. 61
28923625 2017
Pulmonary Papillary Adenoma: Report of Two Cases. 61
29017679 2017
GLUT-1 expression of pulmonary mixed squamous cell and glandular papilloma may be associated with high SUVmax on fluorodeoxyglucose-positron emission tomography. 61
28590021 2017
Expression of p16Ink4a in mixed squamous cell and glandular papilloma of the lung. 61
28470939 2017
Gallbladder papillary neoplasms share pathological features with intraductal papillary neoplasm of the bile duct. 61
28415560 2017

Variations for Papillary Adenoma

Expression for Papillary Adenoma

Search GEO for disease gene expression data for Papillary Adenoma.

Pathways for Papillary Adenoma

GO Terms for Papillary Adenoma

Cellular components related to Papillary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear matrix GO:0016363 9.33 VIM TP53 OGG1
2 multivesicular body lumen GO:0097486 8.96 SFTPC NAPSA
3 alveolar lamellar body GO:0097208 8.62 SFTPC NAPSA

Biological processes related to Papillary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras protein signal transduction GO:0007265 9.43 TP53 KRAS HRAS
2 positive regulation of gene expression GO:0010628 9.35 VIM TP53 NKX2-1 KRAS HRAS
3 epithelial tube branching involved in lung morphogenesis GO:0060441 9.32 NKX2-1 KRAS
4 response to isolation stress GO:0035900 9.16 KRAS HRAS
5 regulation of long-term neuronal synaptic plasticity GO:0048169 8.8 SYP KRAS HRAS

Sources for Papillary Adenoma

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....